Literature DB >> 12792524

Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period.

Aliki G Iniotaki-Theodoraki1, John N Boletis, George Ch Trigas, Helen G Kalogeropoulou, Alkiviadis G Kostakis, Catherine G Stavropoulos-Giokas.   

Abstract

Humoral graft-specific alloreactivity was investigated in 110 renal transplant (RTx) recipients (group A) starting immediately postTx and in 32 RTx candidates sensitized against a failed graft (group B) using an enzyme-linked immunosorbent assay (ELISA) assay. All patients received a human leukocyte antigen (HLA) class I and II incompatible graft. Donor-specific (DS) antibodies were detected in 11 of 110 (90.9%) group-A patients, predominately during the first 6 months postTx. In all 11 cases, only HLA class II antibodies were detected. Ten of 11 antibody-positive patients received an HLA-DR, HLA-DQ incompatible graft, and all patients had HLA-DQ DS antibodies, either alone (n=8) or with HLA-DR antibodies (n=2). HLA-DQ antibodies were also detected in 80.9% of group-B patients. The presence of HLA-DQ DS antibodies in the early postTx period does not identify patients with rejection or deterioration of graft function. Whether these patients are at high risk for graft loss remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12792524     DOI: 10.1097/01.TP.0000061611.51612.09

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP.

Authors:  Rene J Duquesnoy; Medhat Askar
Journal:  Hum Immunol       Date:  2006-10-30       Impact factor: 2.850

2.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

3.  Tailoring antibody testing and how to use it in the calculated panel reactive antibody era: the Northwestern University experience.

Authors:  Anat R Tambur; Joseph Leventhal; Dixon B Kaufman; John Friedewald; Joshua Miller; Michael M Abecassis
Journal:  Transplantation       Date:  2008-10-27       Impact factor: 4.939

4.  Successful renal re-transplantation in the presence of pre-existing anti-DQ5 antibodies when there was zero mismatch at class I human leukocyte antigen A, B, & C: a case report.

Authors:  John Hartono; Bhavna Lavingia; Peter Stastny; Martin Senitko; Miguel Vazquez; Juan Arenas; Christopher Lu
Journal:  J Med Case Rep       Date:  2009-01-30

5.  Patterns of 1,748 Unique Human Alloimmune Responses Seen by Simple Machine Learning Algorithms.

Authors:  Angeliki G Vittoraki; Asimina Fylaktou; Katerina Tarassi; Zafeiris Tsinaris; George Ch Petasis; Demetris Gerogiannis; Vissal-David Kheav; Maryvonnick Carmagnat; Claudia Lehmann; Ilias Doxiadis; Aliki G Iniotaki; Ioannis Theodorou
Journal:  Front Immunol       Date:  2020-07-28       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.